Botulinum neurotoxins (BoNT) are the causative agents of botulism but are also widely used to treat neurological disorders, however, the development of variants with enhanced therapeutic potential remains challenging. Here, the authors identify BoNT/A mutants with enhanced ganglioside-binding and improved potency, and elucidate the molecular mechanism underlying the increased affinity and altered ganglioside selectivity.
- Geoffrey Masuyer
- Andreas Rummel
- Pål Stenmark
